

- This case study investigated an alternative topical treatment for Melanoma *in situ* (MIS).
- Ingenol mebutate is a new treatment for actinic keratosis, but its therapeutic potential on melanocytic lesions is unknown.
- Ingenol mebutate (0.015% gel) was administered on three consecutive days for in situ melanoma.
- One month later, a complete clinical resolution was observed whereas histology and immunohistology revealed no residual tumor.
- In selected cases, ingenol mebutate can be considered as alternative therapy for melanoma in situ, with less cutaneous and without systemic adverse effects compared to imiquimod.

This summary slide represents the opinions of the authors. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).